Ketogenic diet for infantile epileptic spasms
Abstract Approximately half of all cases of Infantile Epileptic Spasms Syndrome (IESS) do not respond to vigabatrin and hormonal therapies. There is no clear consensus as to the second‐line therapy for IESS. Ketogenic diet (KD) has emerged as an effective treatment for certain drug‐resistant epilepsies and in many cases of IESS.
Morris H. Scantlebury +3 more
wiley +1 more source
GABA<sub>A</sub> receptor dysfunction in autism spectrum disorder: molecular mechanisms and therapeutic opportunities. [PDF]
Ragu Varman D +5 more
europepmc +1 more source
Epilepsy surgery: From bench to the clinics
Abstract Objective Recent advances in epilepsy surgery in patients with intractable epilepsy make it possible to study the mechanism of epilepsy in human brains. However, the true extent and propagation of each epileptogenic area from the epileptogenic focus in each patient is still difficult to perform “epilepsy cure” by surgery.
Tatsuya Tanaka
wiley +1 more source
GABA<sub>A</sub> Receptor Modulators as Emerging Therapeutic Agents for Depressive Disorders. [PDF]
Guan BY, Li Y.
europepmc +1 more source
Neonatal seizures and GABAergic drugs: Scylla and Charybdis?
Abstract Neonates have a high incidence of seizures that are frequently difficult to control with conventional first‐line anti‐seizure medications, which are gamma‐aminobutyric acid (GABA) agonists. The reasons for this clinical problem are multifold but are likely related to the unique physiology of the immature nervous system. Specifically, the early
Kerry W. Thompson +2 more
wiley +1 more source
The endogenous cannabinoid system gates plasticity of tonic GABA inhibition. [PDF]
Colangeli R, Conti F.
europepmc +1 more source
Direct modulation of human GABA-A α<sub>1</sub>β<sub>2</sub>γ<sub>2</sub> receptors by the endocannabinoid 2-arachidonoylglycerol: implications for cannabinoid-related ligands and limitations for anxiolytic drug development. [PDF]
Mixcoha E +4 more
europepmc +1 more source
The genetic architecture of epilepsy across molecular mechanisms and clinical heterogeneity
Abstract Epilepsy comprises a highly heterogeneous group of neurological disorders unified by a persistent predisposition to recurrent seizures, yet driven by remarkably diverse genetic, molecular, and network‐level mechanisms. Advances in genomic technologies have revealed that epilepsy arises from a multilayered genetic architecture encompassing rare
Mohammad Reza Seyedtaghia +4 more
wiley +1 more source

